Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.19
ALQA's Cash-to-Debt is ranked lower than
87% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. ALQA: 0.19 )
Ranked among companies with meaningful Cash-to-Debt only.
ALQA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: No Debt Max: No Debt
Current: 0.19
Equity-to-Asset 0.60
ALQA's Equity-to-Asset is ranked lower than
55% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. ALQA: 0.60 )
Ranked among companies with meaningful Equity-to-Asset only.
ALQA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.82 Max: 0.99
Current: 0.6
0.57
0.99
Debt-to-Equity 0.41
ALQA's Debt-to-Equity is ranked lower than
59% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. ALQA: 0.41 )
Ranked among companies with meaningful Debt-to-Equity only.
ALQA' s Debt-to-Equity Range Over the Past 10 Years
Min: -11.11  Med: -0.98 Max: 10.59
Current: 0.41
-11.11
10.59
Debt-to-EBITDA -0.39
ALQA's Debt-to-EBITDA is ranked lower than
99.99% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. ALQA: -0.39 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ALQA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.22  Med: -0.47 Max: -0.07
Current: -0.39
-1.22
-0.07
Piotroski F-Score: 4
Altman Z-Score: -5.58
Beneish M-Score: -4.20
WACC vs ROIC
13.80%
-77.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -174.16
ALQA's Operating Margin % is ranked lower than
90% of the 781 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. ALQA: -174.16 )
Ranked among companies with meaningful Operating Margin % only.
ALQA' s Operating Margin % Range Over the Past 10 Years
Min: -1119.69  Med: -320.39 Max: -51.07
Current: -174.16
-1119.69
-51.07
Net Margin % -185.31
ALQA's Net Margin % is ranked lower than
89% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.12 vs. ALQA: -185.31 )
Ranked among companies with meaningful Net Margin % only.
ALQA' s Net Margin % Range Over the Past 10 Years
Min: -1222.3  Med: -316.99 Max: -52.73
Current: -185.31
-1222.3
-52.73
ROE % -94.87
ALQA's ROE % is ranked lower than
92% of the 803 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.08 vs. ALQA: -94.87 )
Ranked among companies with meaningful ROE % only.
ALQA' s ROE % Range Over the Past 10 Years
Min: -312.57  Med: -69.44 Max: -16.22
Current: -94.87
-312.57
-16.22
ROA % -60.58
ALQA's ROA % is ranked lower than
92% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. ALQA: -60.58 )
Ranked among companies with meaningful ROA % only.
ALQA' s ROA % Range Over the Past 10 Years
Min: -796.05  Med: -57.1 Max: -15.45
Current: -60.58
-796.05
-15.45
ROC (Joel Greenblatt) % -1217.19
ALQA's ROC (Joel Greenblatt) % is ranked lower than
93% of the 817 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.08 vs. ALQA: -1217.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALQA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -53854.55  Med: -1376.37 Max: -55.94
Current: -1217.19
-53854.55
-55.94
3-Year Revenue Growth Rate 37.30
ALQA's 3-Year Revenue Growth Rate is ranked higher than
94% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ALQA: 37.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALQA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 37.3
Current: 37.3
0
37.3
3-Year EBITDA Growth Rate -31.80
ALQA's 3-Year EBITDA Growth Rate is ranked lower than
95% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. ALQA: -31.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALQA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -67.7  Med: 24.1 Max: 109.1
Current: -31.8
-67.7
109.1
3-Year EPS without NRI Growth Rate -28.20
ALQA's 3-Year EPS without NRI Growth Rate is ranked lower than
88% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. ALQA: -28.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALQA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 20.5 Max: 115.4
Current: -28.2
0
115.4
GuruFocus has detected 3 Warning Signs with Alliqua BioMedical Inc ALQA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALQA's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ALQA Guru Trades in Q3 2016

Jim Simons 333,000 sh (+22.65%)
» More
Q4 2016

ALQA Guru Trades in Q4 2016

Jim Simons 410,400 sh (+23.24%)
» More
Q1 2017

ALQA Guru Trades in Q1 2017

Jim Simons 632,800 sh (+54.19%)
» More
Q2 2017

ALQA Guru Trades in Q2 2017

Jim Simons 848,500 sh (+34.09%)
» More
» Details

Insider Trades

Latest Guru Trades with ALQA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2899
Compare:BOM:524470, ASX:IDT, NAS:IMNP, XBUL:59X, OSL:NAVA, HKSE:08225, ASX:RCE, BOM:526953, OTCPK:INNV, AMEX:AXN, BOM:524518, OTCPK:SUWN, HKSE:08019, BOM:524212, SGX:BKZ, BOM:507789, BOM:524500, OSTO:AROC, ROCO:4102, BOM:532305 » details
Traded in other countries:HL1B.Germany,
Headquarter Location:USA
Alliqua BioMedical Inc is a functional regeneration company providing wound care solutions. It is also engaged in contract manufacturing.

Alliqua BioMedical Inc is a functional regeneration company providing wound care solutions. It is also engaged in contract manufacturing.

Top Ranked Articles about Alliqua BioMedical Inc

Alliqua BioMedical, Inc. Announces 1-for-10 Reverse Stock Split
Alliqua BioMedical, Inc. Announces the Sale of TheraBond® 3D Antimicrobial Barrier Systems Product Line; Alliqua Updates Fiscal Year Outlook
Alliqua BioMedical, Inc. to Announce Second Quarter of Fiscal Year 2017 Results on August 10th
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Alliqua BioMedical, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Alliqua BioMedical, Inc. Announces Partnership with Partners Capital Group to Provide UltraMIST® Customers with New Equipment Financing Programs
Alliqua BioMedical, Inc. Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Alliqua BioMedical, Inc. Announces Preliminary First Quarter Fiscal 2017 Revenue and Updates Fiscal Year 2017 Outlook; Earnings Conference Call Scheduled for May 9, 2017
Alliqua BioMedical, Inc. to Present New Data at the Spring 2017 Symposium on Advanced Wound Care
Alliqua BioMedical, Inc. Announces Closing of Approximately $3.8 Million Public Offering
Alliqua BioMedical, Inc. Announces Proposed Public Offering of Common Stock

YARDLEY, Pa., March 28, 2017 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"), a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Alliqua also expects to grant the underwriter a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., is acting as the sole underwriter for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, and to pay the Company’s monthly payment obligations under its credit agreement with Perceptive Credit Opportunities Fund, L.P. A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission ("SEC") and was declared effective on September 25, 2014. A preliminary prospectus supplement describing the terms of the offering will be filed with the SEC and will form a part of the effective registration statement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from H.C. Wainwright & Co., LLC, 430 Park Avenue 4th Floor, New York, NY 10022, or by calling (646) 975-6957 or by emailing [email protected] or at the SEC's website at http://www.sec.gov. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Alliqua BioMedical, Inc. Alliqua is a regenerative technologies company committed to restoring tissue and rebuilding lives. Through its sales and distribution network, together with its proprietary products, Alliqua offers solutions that allow clinicians to utilize the latest advances in regenerative technologies to bring improved patient outcomes to their practices. Alliqua currently markets the human biologic regenerative technologies, Biovance® and Interfyl™. The Company also markets its Mist Therapy System®, which uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. In addition to these technologies, Alliqua markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. The Company has locations in Yardley, Pennsylvania, Langhorne, Pennsylvania and Eden Prairie, Minnesota. For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.  Legal Notice Regarding Forward-Looking Statements: This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, our expectations on the completion, timing and size of the public offering and the anticipated use of proceeds therefrom, the adequacy of the Company’s liquidity to pursue its complete business objectives; inadequate capital; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans.  In addition, other factors that could cause actual results to differ materially are discussed in our filings with the SEC, including our most recent Annual Report on Form 10-K filed with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
Investor Relations:
Westwicke Partners on behalf of Alliqua BioMedical, Inc.
Mike Piccinino, CFA 1-443-213-0500
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.55
ALQA's PB Ratio is ranked higher than
95% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. ALQA: 0.55 )
Ranked among companies with meaningful PB Ratio only.
ALQA' s PB Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.31 Max: 23.16
Current: 0.55
0.37
23.16
PS Ratio 0.54
ALQA's PS Ratio is ranked higher than
90% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. ALQA: 0.54 )
Ranked among companies with meaningful PS Ratio only.
ALQA' s PS Ratio Range Over the Past 10 Years
Min: 0.43  Med: 9.7 Max: 38.53
Current: 0.54
0.43
38.53
EV-to-EBIT -0.74
ALQA's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.28 vs. ALQA: -0.74 )
Ranked among companies with meaningful EV-to-EBIT only.
ALQA' s EV-to-EBIT Range Over the Past 10 Years
Min: -20.5  Med: -2.5 Max: -0.5
Current: -0.74
-20.5
-0.5
EV-to-EBITDA -0.85
ALQA's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.61 vs. ALQA: -0.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALQA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -99  Med: -2.7 Max: -0.5
Current: -0.85
-99
-0.5
EV-to-Revenue 1.28
ALQA's EV-to-Revenue is ranked higher than
78% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.07 vs. ALQA: 1.28 )
Ranked among companies with meaningful EV-to-Revenue only.
ALQA' s EV-to-Revenue Range Over the Past 10 Years
Min: 1  Med: 10.4 Max: 51.1
Current: 1.28
1
51.1
Current Ratio 0.48
ALQA's Current Ratio is ranked lower than
98% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. ALQA: 0.48 )
Ranked among companies with meaningful Current Ratio only.
ALQA' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 1.61 Max: 96.93
Current: 0.48
0.04
96.93
Quick Ratio 0.33
ALQA's Quick Ratio is ranked lower than
98% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. ALQA: 0.33 )
Ranked among companies with meaningful Quick Ratio only.
ALQA' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 1.27 Max: 96.93
Current: 0.33
0.04
96.93
Days Inventory 151.42
ALQA's Days Inventory is ranked lower than
66% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 120.98 vs. ALQA: 151.42 )
Ranked among companies with meaningful Days Inventory only.
ALQA' s Days Inventory Range Over the Past 10 Years
Min: 11.87  Med: 63.83 Max: 151.42
Current: 151.42
11.87
151.42
Days Sales Outstanding 65.41
ALQA's Days Sales Outstanding is ranked higher than
58% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. ALQA: 65.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALQA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.55  Med: 44.64 Max: 73.9
Current: 65.41
13.55
73.9
Days Payable 140.69
ALQA's Days Payable is ranked higher than
80% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 68.69 vs. ALQA: 140.69 )
Ranked among companies with meaningful Days Payable only.
ALQA' s Days Payable Range Over the Past 10 Years
Min: 24.61  Med: 123.53 Max: 196.17
Current: 140.69
24.61
196.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -37.20
ALQA's 3-Year Average Share Buyback Ratio is ranked lower than
90% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. ALQA: -37.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALQA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67.4  Med: -18.6 Max: 29.7
Current: -37.2
-67.4
29.7

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.05
ALQA's Price-to-Median-PS-Value is ranked higher than
99% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.04 vs. ALQA: 0.05 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALQA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 1.02 Max: 3.62
Current: 0.05
0.05
3.62
Earnings Yield (Greenblatt) % -137.19
ALQA's Earnings Yield (Greenblatt) % is ranked lower than
99% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. ALQA: -137.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALQA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -212.7  Med: -39.7 Max: -4.9
Current: -137.19
-212.7
-4.9

More Statistics

Revenue (TTM) (Mil) $19.93
EPS (TTM) $ -12.30
Beta1.11
Short Percentage of Float2.93%
52-Week Range $2.30 - 8.50
Shares Outstanding (Mil)4.90

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 19 22 28 35
EPS ($) -3.90 -2.00 -0.90 -0.50
EPS without NRI ($) -3.90 -2.00 -0.90 -0.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}